Cover Image
市場調查報告書

PharmaPoint:神經病變性疼痛--全球醫藥品的預測與市場分析

PharmaPoint: Neuropathic Pain - Global Drug Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 314722
出版日期 內容資訊 英文 423 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:神經病變性疼痛--全球醫藥品的預測與市場分析 PharmaPoint: Neuropathic Pain - Global Drug Forecast and Market Analysis to 2022
出版日期: 2014年04月30日 內容資訊: 英文 423 Pages
簡介

神經性病變痛(NP)是感覺運動系統的障礙,和傷害性疼痛(外傷、傷害、發炎造成的疼痛)儼然不同。神經性病變疼痛與傷害性疼痛主要差別在於神經性病變疼痛並沒有持續性地刺激傷害受體。尤其是糖尿病神經痛(PDN)、帶狀疱疹後神經痛、三叉神經痛等三個主要症狀。目前所使用的藥劑主要層級有抗驚厥劑、抗憂鬱劑、鴉片類藥物及局部治療等。但儘管有各種治療藥,仍僅有50%的患者顯示有療效,同時還會產生各種副作用,造成耐受性降低。新治療法在效能、耐受性方面雖然滿足了部分未滿足需求,但仍留有更高可靠性、安全性的需求在。

本報告提供全球主要7個國家的神經病變性止痛法相關的最新研究·開發情形及市場未來展望分析,彙整疾病概要和治療方法,市場機會及未滿足需求,市場規模趨勢(今後10年份),已上市/臨床實驗中主要的治療藥簡介(功效·安全性·市場競爭力),全球整體·各國市場的現狀與今後的方向性等資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 神經病變性疼痛臨床症狀:前兆·症狀
    • 糖尿病神經痛(PDN)
    • 帶狀皰疹後神經痛(PHN)
    • 三叉神經痛(TN)
  • 病因·病理
    • 病因
    • 病理生理學

第4章 流行病學

  • 糖尿病神經病變
    • 疾病的背景情況
    • 風險要素和合併症
    • 全球的趨勢
    • 預測手法
    • 流行病學的預測(今後10年份)
    • 爭議
  • 帶狀皰疹後神經痛
  • 三叉神經痛

第5章 疾病的管理

  • 診斷·治療概要
    • 診斷
    • 治療方法的概要與指南
  • 美國
    • 診斷·轉診途徑
    • 藥物療法
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第6章 競爭企業的評估

  • 概要
  • 三環系抗憂鬱劑
    • 概要
    • 功效
    • 安全性
    • 未來預測
  • 鈣離子通道α-2-δ配體(抗痙攣藥)
    • Lyrica
  • 鈉離子通道阻斷抗痙攣藥(TN)
  • 正腎上腺素再吸收抑制劑(抗憂鬱劑)
    • Cymbalta
  • Opioids(類鴉片物質)
    • Nucynta ER/Palexia SR
  • 局部療法
    • Lidoderm/Versatis
    • Qutenza

第7章 未滿足需求與市場機會

  • 概要
  • 醫生的知識/認知度
    • 未滿足需求
    • 差距分析
    • 市場機會
  • 診斷上的課題
  • 低治療率與給藥量少
  • 對藥理學性治療的功效·安全性方面的不滿
  • 高齡患者:藥物的耐受性
  • 合理的/個人化醫療

第8章 開發平台評估

  • 概要
  • 臨床實驗製圖
    • 臨床實驗的進展:患者族群別
  • 臨床實驗中的有潛力的藥劑
    • Eslicarbazepine Acetate
    • Topical Clonidine Gel
    • Cebranopadol
    • DS-5565
    • CNV-2197944
    • CNV-1014802
    • Eladur (bupivacaine patch)

第9章 現在·未來市場參與企業

  • 概要
  • 企業策略的趨勢
  • 企業簡介
    • Pfizer
    • Eli Lilly
    • Grunenthal
    • Endo Health Solutions
    • Janssen Pharmaceuticals
    • 第一三共
    • Convergence Pharmaceuticals

第10章 市場未來展望

  • 全球市場
    • 未來預測
    • 市場促進·阻礙因素:全球整體的情況
  • 美國
    • 未來預測
    • 近幾年主要的事件
    • 市場促進·阻礙因素
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第11章 附錄

圖表一覽

目錄

Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability. New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.

Highlights

Key Questions Answered

  • The neuropathic pain market is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market Will the drugs under development fulfil the unmet needs of the neuropathic pain market
  • What differences exist in the current disease management across the 3 NP indications, and across the 7 markets
  • What are the views of KOLs on the present and future landscape of the neuropathic pain market
  • Several brands of neuropathic pain drugs are due for patent expiry. How will the patent expiries impact the neuropathic pain therapeutics market
  • The developmental pipeline consists of several novel drugs. Which of these drugs will attain high sales revenues during 2012-2022

Key Findings

  • The main driver for the expansion of the NP market will be the increasing NP incidence due to 2 main reasons: the growing elderly population
  • And the increase in the prevalence and diagnosis of type 2 diabetes which will lead to growth of the painful diabetic neuropathy (PDN) market - the largest NP segment.
  • Additionally, the approval of novel formulations and first-in-class therapies in pipeline for NP that will drive sales in this market
  • The greatest barrier to growth in this market will be the fact that the key market leading drugs will go off patent during the forecast period leading to a NP market largely dominated by generics, which raises the barrier to entry for novel drug therapies.

Scope

  • Overview of 3 neuropathic pain indications - painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized neuropathic pain therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for 10 years to 2022.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the neuropathic pain therapeutics market.
  • Pipeline analysis: focus on mid to late-stage pipeline drugs discussing emerging trends as well as overview of earlier phase drugs.
  • Analysis of the current and future market competition in the global neuropathic pain therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global neuropathic pain therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global neuropathic pain therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global neuropathic pain therapeutics market from 2012-2022.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Clinical Manifestations of Neuropathic Pain - Signs and Symptoms
    • 3.1.1. Painful Diabetic Neuropathy
    • 3.1.2. Postherpetic Neuralgia
    • 3.1.3. Trigeminal Neuralgia
  • 3.2. Etiology and Pathophysiology
    • 3.2.1. Etiology
    • 3.2.2. Pathophysiology

4. Epidemiology

  • 4.1. Diabetic Neuropathy
    • 4.1.1. Disease Background
    • 4.1.2. Risk Factors and Comorbidities
    • 4.1.3. Global Trends
    • 4.1.4. Forecast Methodology
    • 4.1.5. Epidemiology Forecast for Diabetic Neuropathy (2012-2022)
    • 4.1.6. Discussion
  • 4.2. Postherpetic Neuralgia
    • 4.2.1. Disease Background
    • 4.2.2. Risk Factors and Comorbidities
    • 4.2.3. Global Trends
    • 4.2.4. Forecast Methodology
    • 4.2.5. Epidemiological Forecast for Postherpetic Neuralgia (2012-2022)
    • 4.2.6. Discussion
  • 4.3. Trigeminal Neuralgia
    • 4.3.1. Disease Background
    • 4.3.2. Risk Factors and Comorbidities
    • 4.3.3. Global Trends
    • 4.3.4. Forecast Methodology
    • 4.3.5. Epidemiological Forecast for Trigeminal Neuralgia (2012-2022) - Incident Cases
    • 4.3.6. Epidemiological Forecast for Trigeminal Neuralgia (2012-2022) - Prevalent Cases
    • 4.3.7. Discussion

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Diagnosis
    • 5.1.2. Treatment Overview and Guidelines
  • 5.2. US
    • 5.2.1. Diagnosis and Referral
    • 5.2.2. Drug Treatment
  • 5.3. France
    • 5.3.1. Diagnosis and Referral
    • 5.3.2. Drug Treatment
  • 5.4. Germany
    • 5.4.1. Diagnosis and Referral
    • 5.4.2. Drug Treatment
  • 5.5. Italy
    • 5.5.1. Diagnosis and Referral
    • 5.5.2. Drug Treatment
  • 5.6. Spain
    • 5.6.1. Diagnosis and Referral
    • 5.6.2. Drug Treatment
  • 5.7. UK
    • 5.7.1. Diagnosis and Referral
    • 5.7.2. Drug Treatment
  • 5.8. Japan
    • 5.8.1. Diagnosis and Referral
    • 5.8.2. Drug Treatment

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Tricyclic Antidepressants
    • 6.2.1. Overview
    • 6.2.2. Efficacy
    • 6.2.3. Safety
    • 6.2.4. Forecast
  • 6.3. Calcium Channel Alpha-2-Delta Ligands (Anticonvulsants)
    • 6.3.1. Overview
    • 6.3.2. Efficacy
    • 6.3.3. Safety
    • 6.3.4. Forecast
    • 6.3.5. Lyrica
  • 6.4. Sodium Channel-Blocking Anticonvulsants (TN)
    • 6.4.1. Overview
    • 6.4.2. Efficacy
    • 6.4.3. Safety
    • 6.4.4. Forecast
  • 6.5. Serotonin-Norepinephrine Reuptake Inhibitors (Antidepressants)
    • 6.5.1. Overview
    • 6.5.2. Efficacy
    • 6.5.3. Safety
    • 6.5.4. Forecast
    • 6.5.5. Cymbalta
  • 6.6. Opioids
    • 6.6.1. Overview
    • 6.6.2. Efficacy
    • 6.6.3. Safety
    • 6.6.4. Forecast
    • 6.6.5. Nucynta ER/Palexia SR
  • 6.7. Topical Therapies
    • 6.7.1. Overview
    • 6.7.2. Efficacy
    • 6.7.3. Safety
    • 6.7.4. Forecast
    • 6.7.5. Lidoderm/Versatis
    • 6.7.6. Qutenza

7. Unmet Need and Opportunity

  • 7.1. Overview
  • 7.2. Physician Knowledge or Awareness
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Diagnostic Challenges
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Low Treatment Rate and Underdosing of Medications
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Unsatisfactory Efficacy and Safety Profiles of Pharmacological Treatments
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. Elderly Patient Population - Drug Tolerability
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity
  • 7.7. Rational or Personalized Therapies
    • 7.7.1. Unmet Need
    • 7.7.2. Gap Analysis
    • 7.7.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Patient Population
  • 8.3. Promising Drugs in Clinical Development
    • 8.3.1. Eslicarbazepine Acetate
    • 8.3.2. Topical Clonidine Gel
    • 8.3.3. Cebranopadol
    • 8.3.4. DS-5565
    • 8.3.5. CNV-2197944
    • 8.3.6. CNV-1014802
    • 8.3.7. Eladur (bupivacaine patch)

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Pfizer
    • 9.3.2. Eli Lilly
    • 9.3.3. Grunenthal
    • 9.3.4. Endo Health Solutions
    • 9.3.5. Janssen Pharmaceuticals
    • 9.3.6. Daiichi Sankyo
    • 9.3.7. Convergence Pharmaceuticals

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. United States
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. France
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Germany
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Italy
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Spain
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. United Kingdom
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers
  • 10.8. Japan
    • 10.8.1. Forecast
    • 10.8.2. Key Events
    • 10.8.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed PDN, PHN, and TN Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Drugs Included In Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline Agents
  • 11.5. Physicians and Specialists Included in This Study
  • 11.6. About the Authors
    • 11.6.1. Author
    • 11.6.2. Epidemiologists
    • 11.6.3. Global Head of Healthcare
  • 11.7. About GlobalData
  • 11.8. Disclaimer

List of Tables

  • Table 1: Classification of NP Syndromes Based on the Site of Somatosensory Damage
  • Table 2: Signs and Symptoms of NP
  • Table 3: NP Descriptor Terms
  • Table 4: 7MM, Sources of Diabetic Neuropathy Total Prevalence Data
  • Table 5: 7MM, Excluded Sources of Diabetic Neuropathy Total Prevalence Data
  • Table 6: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, Both Sexes, Ages ≥40 Years, N, 2012-2022
  • Table 7: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, Both Sexes, by Age, N, Row (%), 2012
  • Table 8: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, by Sex, Ages ≥40 Years, N, Row (%), 2012
  • Table 9: 7MM, Sources of PHN Incidence Data
  • Table 10: 7MM, Incident Cases of PHN, Ages ≥50 Years, Men and Women, N, 2012-2022
  • Table 11: 7MM, Incident Cases of PHN, by Age, Men and Women, N (Row %), 2012
  • Table 12: 7MM, Incident Cases of PHN, by Sex, Ages ≥50 Years, N (Row %), 2012
  • Table 13: Epidemiological Data for TN
  • Table 14: 7MM, Sources of TN Incidence Data
  • Table 15: 7MM, Sources of TN Prevalence Data
  • Table 16: 7MM, Incident Cases of TN, Ages ≥50 Years, Men and Women, N, 2012-2022
  • Table 17: 7MM, Incident Cases of TNa, by Age, Men and Women, N, (Row %), 2012
  • Table 18: 7MM, Incident Cases of TN, by Sex, Ages ≥50 Years, N (Row %), 2012
  • Table 19: 7MM, Prevalent Cases of TN, Ages ≥50 Years, Men and Women, N, 2012-2022
  • Table 20: 7MM, Prevalent Cases of TN, by Age, Men and Women, N, (Row %), 2012
  • Table 21: 7MM, Prevalent Cases of TN, by Sex, Ages ≥50 Years, N (Row %), 2012
  • Table 22: Screening Tools for NP
  • Table 23: NP-Related Signs and Symptoms
  • Table 24: Treatment Guidelines for NP
  • Table 25: Recommended Drug Therapies for NP Conditions by Line of Therapy
  • Table 26: Most Prescribed Drugs for NP by Indication and Line of Therapy in the Global Markets, 2012
  • Table 27: US - NP Diagnosis and Referral Metrics
  • Table 28: US - NP Treatment Metrics
  • Table 29: France - NP Diagnosis and Referral Metrics
  • Table 30: France - NP Treatment Metrics
  • Table 31: Germany - NP Diagnosis and Referral Metrics
  • Table 32: Germany - NP Treatment Metrics
  • Table 33: Italy - NP Diagnosis and Referral Metrics
  • Table 34: Italy - NP Treatment Metrics
  • Table 35: Spain - NP Diagnosis and Referral Metrics
  • Table 36: Spain - NP Treatment Metrics
  • Table 37: UK - NP Diagnosis and Referral Metrics
  • Table 38: UK - NP Treatment Metrics
  • Table 39: Japan - NP Diagnosis and Referral Metrics
  • Table 40: Japan - NP Treatment Metrics
  • Table 41: NNT and NNH for Classes of Oral Drugs used in NP Treatment, 2013
  • Table 42: Select Products Used for NP Treatment, 2013
  • Table 43: Global Sales Forecasts ($m) for TCAs, 2012-2022
  • Table 44: Global Sales Forecasts ($m) for Calcium Channel Alpha-2-Delta Ligands, 2012-2022
  • Table 45: Product Profile - Lyrica
  • Table 46: Lyrica SWOT Analysis, 2013
  • Table 47: Global Sales Forecasts ($m) for Lyrica, 2012-2022
  • Table 48: Global Sales Forecasts ($m) for Sodium Channel-Blocking Anticonvulsants, 2012-2022
  • Table 49: Global Sales Forecasts ($m) for SNRIs, 2012-2022
  • Table 50: Product Profile - Cymbalta
  • Table 51: Cymbalta SWOT Analysis, 2013
  • Table 52: Global Sales Forecasts ($m) for Cymbalta, 2012-2022
  • Table 53: Global Sales Forecasts ($m) for Opioids, 2012-2022
  • Table 54: Product Profile - Nucynta ER/Palexia SR
  • Table 55: Nucynta ER/Palexia SR SWOT Analysis, 2013
  • Table 56: Global Sales Forecasts ($m) for Nucynta ER/Palexia SR, 2012-2022
  • Table 57: Global Sales Forecasts ($m) for Topical Therapies, 2012-2022
  • Table 58: Product Profile - Lidoderm/Versatis
  • Table 59: Lidoderm/Versatis SWOT Analysis, 2013
  • Table 60: Global Sales Forecasts ($m) for Lidoderm/Versatis, 2012-2022
  • Table 61: Product Profile - Qutenza
  • Table 62: Qutenza SWOT Analysis, 2013
  • Table 63: Global Sales Forecasts ($m) for Qutenza, 2012-2022
  • Table 64: Unmet Need and Opportunity in NP
  • Table 65: NP - Promising Drugs in Clinical Development
  • Table 66: Comparison of Drugs in Development for NP, 2014
  • Table 67: Product Profile - Eslicarbazepine Acetate
  • Table 68: Phase II: Efficacy of Eslicarbazepine Acetate in PHN
  • Table 69: Phase II: Efficacy of Eslicarbazepine Acetate in PDN
  • Table 70: Eslicarbazepine Acetate SWOT Analysis, 2013
  • Table 71: Global Sales Forecasts ($m) for Eslicarbazepine Acetate, 2012-2022
  • Table 72: Product Profile - Topical Clonidine Gel
  • Table 73: Topical Clonidine Gel SWOT Analysis, 2013
  • Table 74: Global Sales Forecasts ($) for Topical Clonidine Gel, 2012-2022
  • Table 75: Product Profile - Cebranopadol
  • Table 76: Cebranopadol SWOT Analysis, 2013
  • Table 77: Global Sales Forecasts ($) for Cebranopadol, 2012-2022
  • Table 78: Product Profile - DS-5565
  • Table 79: DS-5565 SWOT Analysis, 2013
  • Table 80: Global Sales Forecasts ($) for DS-5565, 2012-2022
  • Table 81: Product Profile - CNV-2197944
  • Table 82: CNV-2197944 SWOT Analysis, 2013
  • Table 83: Global Sales Forecasts ($m) for CNV-2197944, 2012-2022
  • Table 84: Product Profile - CNV1014802
  • Table 85: CNV-1014802 SWOT Analysis, 2013
  • Table 86: Global Sales Forecasts ($) for CNV-1014802, 2012-2022
  • Table 87: Product Profile - Eladur
  • Table 88: Eladur SWOT Analysis, 2013
  • Table 89: Global Sales Forecasts ($) for Eladur, 2012-2022
  • Table 90: Key Companies in the NP Market, 2014
  • Table 91: Pfizer's NP Portfolio Assessment, 2014
  • Table 92: Pfizer SWOT Analysis, 2013
  • Table 93: Eli Lilly's NP Portfolio Assessment, 2013
  • Table 94: Eli Lilly SWOT Analysis, 2013
  • Table 95: Grunenthal's NP Portfolio Assessment, 2013
  • Table 96: Grunenthal SWOT Analysis, 2013
  • Table 97: Endo Health Solutions' NP Portfolio Assessment, 2013
  • Table 98: Endo Health Solutions SWOT Analysis, 2013
  • Table 99: Janssen Pharmaceuticals' NP Portfolio Assessment, 2013
  • Table 100: Janssen Pharmaceuticals SWOT Analysis, 2013
  • Table 101: Daiichi Sankyo's NP Portfolio Assessment, 2013
  • Table 102: Daiichi Sankyo SWOT Analysis, 2013
  • Table 103: Convergence Pharmaceuticals' NP Portfolio Assessment, 2013
  • Table 104: Convergence Pharmaceuticals SWOT Analysis, 2013
  • Table 105: Global Sales Forecasts ($) for NP, 2012-2022
  • Table 106: Global Sales Forecasts ($) for PDN, 2012-2022
  • Table 107: Global Sales Forecasts ($) for PHN, 2012-2022
  • Table 108: Global Sales Forecasts ($) for TN, 2012-2022
  • Table 109: NP Market - Drivers and Barriers, 2012-2022
  • Table 110: Sales Forecasts ($) for NP in the United States, 2012-2022
  • Table 111: Sales Forecasts ($) for PDN in the United States, 2012-2022
  • Table 112: Sales Forecasts ($) for PHN in the United States, 2012-2022
  • Table 113: Sales Forecasts ($) for TN in the United States, 2012-2022
  • Table 114: Key Events Impacting Sales for NP in the United States, 2012-2022
  • Table 115: NP Market - Drivers and Barriers in the United States, 2012-2022
  • Table 116: Sales Forecasts ($) for NP in France, 2012-2022
  • Table 117: Sales Forecasts ($) for PDN in France, 2012-2022
  • Table 118: Sales Forecasts ($) for PHN in France, 2012-2022
  • Table 119: Sales Forecasts ($) for TN in France, 2012-2022
  • Table 120: Key Events Impacting Sales for NP in France, 2012-2022
  • Table 121: NP Market- Drivers and Barriers in France, 2012-2022
  • Table 122: Sales Forecasts ($) for NP in Germany, 2012-2022
  • Table 123: Sales Forecasts ($) for PDN in Germany, 2012-2022
  • Table 124: Sales Forecasts ($) for PHN in Germany, 2012-2022
  • Table 125: Sales Forecasts ($) for TN in Germany, 2012-2022
  • Table 126: Key Events Impacting Sales for NP in Germany, 2012-2022
  • Table 127: NP Market - Drivers and Barriers in Germany, 2012-2022
  • Table 128: Sales Forecasts ($) for NP in Italy, 2012-2022
  • Table 129: Sales Forecasts ($) for PDN in Italy, 2012-2022
  • Table 130: Sales Forecasts ($) for PHN in Italy, 2012-2022
  • Table 131: Sales Forecasts ($) for TN in Italy, 2012-2022
  • Table 132: Key Events Impacting Sales for NP in Italy, 2012-2022
  • Table 133: NP Market- Drivers and Barriers in Italy, 2012-2022
  • Table 134: Sales Forecasts ($) for NP in Spain, 2012-2022
  • Table 135: Sales Forecasts ($) for PDN in Spain, 2012-2022
  • Table 136: Sales Forecasts ($) for PHN in Spain, 2012-2022
  • Table 137: Sales Forecasts ($) for TN in Spain, 2012-2022
  • Table 138: Key Events Impacting Sales for NP in Spain, 2012-2022
  • Table 139: NP Market- Drivers and Barriers in Spain, 2012-2022
  • Table 140: Sales Forecasts ($) for NP in the UK, 2012-2022
  • Table 141: Sales Forecasts ($) for PDN in the UK, 2012-2022
  • Table 142: Sales Forecasts ($) for PHN in the UK, 2012-2022
  • Table 143: Sales Forecasts ($) for TN in the UK, 2012-2022
  • Table 144: Key Events Impacting Sales for NP in the UK, 2012-2022
  • Table 145: NP Market - Drivers and Barriers in the UK, 2012-2022
  • Table 146: Sales Forecasts ($) for NP in Japan, 2012-2022
  • Table 147: Sales Forecasts ($) for PDN in Japan, 2012-2022
  • Table 148: Sales Forecasts ($) for PHN in Japan, 2012-2022
  • Table 149: Sales Forecasts ($) for TN in Japan, 2012-2022
  • Table 150: Key Events Impacting Sales for NP in Japan, 2012-2022
  • Table 151: NP Market - Drivers and Barriers in Japan, 2012-2022
  • Table 152: Key Launch Dates
  • Table 153: Key Patent/Exclusivity Expiries

List of Figures

  • Figure 1: Nociceptive Versus Neuropathic Pain
  • Figure 2: Etiology and Pathophysiology of NP
  • Figure 3: Pain Pathway - Somatosensory System
  • Figure 4: Pathophysiological Mechanisms of NP at Different Levels of the Nervous System
  • Figure 5: Pathophysiological Targets of NP Drugs
  • Figure 6: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, Both Sexes, Ages ≥40 Years, N, 2012-2022
  • Figure 7: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, Both Sexes, by Age, N, 2012
  • Figure 8: 7MM, Total Prevalent Cases of Diabetic Neuropathy in Diagnosed Diabetics, by Sex, Ages ≥40 Years, N, 2012
  • Figure 9: 7MM, Comorbid Hypertension in Diabetic Neuropathy Cases (N), Both Sexes, Ages ≥40, 2012
  • Figure 10: 7MM, Incident Cases of PHN, Ages ≥50 Years, Men and Women, N, 2012-2022
  • Figure 11: 7MM, Incident Cases of PHN, by Age, Men and Women, N, 2012
  • Figure 12: 7MM, Incident Cases of PHN, by Sex, Ages ≥50 Years, N, 2012
  • Figure 13: 7MM, Age-Standardized Incidence of PHN (per 1,000 Population), Ages ≥50 Years, Men and Women, 2012
  • Figure 14: 7MM, Incident Cases of TN, Ages ≥50 Years, Men and Women, N, 2012-2022
  • Figure 15: 7MM, Incident Cases of TN, by Age, Men and Women, N, 2012
  • Figure 16: 7MM, Incident Cases of TN, by Sex, Ages ≥50 Years, N, 2012
  • Figure 17: 7MM, Age-Standardized Incidence of TN (per 100,000 Population), Ages ≥50 Years, Men and Women, 2012
  • Figure 18: 7MM, Prevalent Cases of TN, Ages ≥50 Years, Men and Women, N, 2012-2022
  • Figure 19: 7MM, Prevalent Cases of TN, by Age, Men and Women, N, 2012
  • Figure 20: 7MM, Prevalent Cases of TN, by Sex, Ages ≥50 Years, N, 2012
  • Figure 21: NeuSPIG Diagnostic Certainty Algorithm for NP
  • Figure 22: General Treatment Algorithm for NP
  • Figure 23: NP Therapeutics - Number of Phase II and III Clinical Trials in Each Indication in the 7MM
  • Figure 24: Competitive Assessment of Mid-to-Late Stage Pipeline Agents in NP, 2012-2022
  • Figure 25: Company Portfolio Gap Analysis in NP, 2012-2022
  • Figure 26: Global Sales for NP by Region, 2012-2022
  • Figure 27: Global Sales for PDN by Drug Class, 2012-2022
  • Figure 28: Global Sales for PHN by Drug Class, 2012-2022
  • Figure 29: Global Sales for TN by Drug Class, 2012-2022
  • Figure 30: Sales for NP in the United States by Drug Class, 2012-2022
  • Figure 31: Sales for PDN in the United States by Drug Class, 2012-2022
  • Figure 32: Sales for PHN in the United States by Drug Class, 2012-2022
  • Figure 33: Sales for TN in the United States by Drug Class, 2012-2022
  • Figure 34: Sales for NP in France by Drug Class, 2012-2022
  • Figure 35: Sales for PDN in France by Drug Class, 2012-2022
  • Figure 36: Sales for PHN in France by Drug Class, 2012-2022
  • Figure 37: Sales for TN in France by Drug Class, 2012-2022
  • Figure 38: Sales for NP in Germany by Drug Class, 2012-2022
  • Figure 39: Sales for PDN in Germany by Drug Class, 2012-2022
  • Figure 40: Sales for PHN in Germany by Drug Class, 2012-2022
  • Figure 41: Sales for TN in Germany by Drug Class, 2012-2022
  • Figure 42: Sales for NP in Italy by Drug Class, 2012-2022
  • Figure 43: Sales for PDN in Italy by Drug Class, 2012-2022
  • Figure 44: Sales for PHN in Italy by Drug Class, 2012-2022
  • Figure 45: Sales for TN in Italy by Drug Class, 2012-2022
  • Figure 46: Sales for NP in Spain by Drug Class, 2012-2022
  • Figure 47: Sales for PDN in Spain by Drug Class, 2012-2022
  • Figure 48: Sales for PHN in Spain by Drug Class, 2012-2022
  • Figure 49: Sales for TN in Spain by Drug Class, 2012-2022
  • Figure 50: Sales for NP in the UK by Drug Class, 2012-2022
  • Figure 51: Sales for PDN in the UK by Drug Class, 2012-2022
  • Figure 52: Sales for PHN in the UK by Drug Class, 2012-2022
  • Figure 53: Sales for TN in the UK by Drug Class, 2012-2022
  • Figure 54: Sales for NP in Japan by Drug Class, 2012-2022
  • Figure 55: Sales for PDN in Japan by Drug Class, 2012-2022
  • Figure 56: Sales for PHN in Japan by Drug Class, 2012-2022
  • Figure 57: Sales for TN in Japan by Drug Class, 2012-2022
Back to Top